European Society for Medical Oncology Congress

In this video, Eugene Shenderov, MD, PhD, assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, MD, discusses the Phase 3 VISION trial.

In this video, Eugene Shenderov, MD, PhD, discusses the STAMPEDE and PEACE-1 studies, which evaluated the addition of abiraterone acetate plus prednisolone to standard therapy for patients with prostate cancer.

In this video, Stacy Loeb, MD, professor in the department of urology at NYU Grossman School of Medicine, discusses studies looking at genetic counseling and its effect on the management of advanced prostate cancer.

In this video, Stacy Loeb, MD, professor in the department of urology at NYU Grossman School of Medicine, discusses two studies about prostate cancer at the AUA Annual Meeting.

In this video, Ben Tran, MD, discusses the PEACE-1 and STAMPEDE studies that looked at the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy, which was found to improve survival vs. standard therapy.

In this video, Edward B. Garon, MD, MS, discusses findings from lung cancer studies, including the DESTINY-Lung01 trial, presented at ESMO 2021.

In this video, Edward B. Garon, MD, MS, discusses findings from the TROPION-PanTumor01 study presented at ESMO 2021.

Reduction in circulating tumor DNA appeared correlated with longer OS among patients with previously treated metastatic uveal melanoma who received tebentafusp, according to study results presented at the virtual ESMO Congress.

In an interview with Healio, Pasi A. Jänne, MD, PhD, discussed a study on the use of an antibody-drug conjugate in some patients with non-small cell lung cancer.

In a video interview, Nancy U. Lin, MD, discussed the DESTINY-Breast12 trial in progress presented at the virtual ESMO Congress.